Bitte wählen Sie:

Universitätsklinikum Essen
Direkteinstieg:
Forschung & Lehre

Arbeitsgruppe

Experimentelle Gastroenterologie

Prof. Dr. med. Elke Cario

Institutsgruppe I, Bauteil C
Räume 7.005 - 7.008b


Research Focus / Forschungsschwerpunkt

(pdf version)

Immune tolerance to commensal microbiota represents an essential host defence mechanism in order to maintain mucosal hyporesponsiveness in the healthy intestine. In order to avoid overactive and inappropriate immune responses in the intestinal mucosa which may trigger inflammatory disease, TLR (Toll-like receptor) signalling must be tightly controlled. In previous work we have demonstrated that TLR2 exerts important barrier-protective functions in the intestinal epithelium. But emerging evidence suggests that the function of TLR2 is context-dependent and the net result depends on the predominant cell types involved. Intolerance between gut microbiota and mucosal immunity through aberrant TLR2 signalling has recently been implicated in the pathogenesis of inflammatory bowel disease (IBD). My lab explores the signalling mechanisms that prevent TLR2-mediated detrimental and inappropriate inflammatory responses in a cell-specific manner and thus critically assist the innate immune system in preserving mucosal homeostasis in the intestine.

The intestinal epithelial cell (IEC) layer serves as an important defensive barrier of the mucosal immune system that forms a bipolar interface between the vast variety of commensals and other antigens of the lumen and subjacent immune cells present in the lamina propria. 3D-cell culture technologies have become available that allow long-term culture of human primary IEC ex-vivo. Our goal is to define the complex mechanistics and functional diversity of IEC innate immunity and determine how this apparatus shapes mucosal homeostasis of the intestine. Using defined standard operating procedures, we have generated human-derived intestinal epithelial organoids from control and patient biopsies (IBD) and surgical specimens (colorectal cancer) and now characterize morphology, proliferation, survival and other cellular functions during long-term growth and cell stimulation experiments. Our aim is to identify novel therapeutic targets for the treatment of major GI disorders that affect the intestinal epithelium. For instance, we have recently shown that adding a TLR2 agonist to 3D-cultures of human colonic biopsies preserves intestinal epithelial tight junctional integrity and polarization ex-vivo.

Intestinal mucositis represents a common complication and dose-limiting toxicity of cancer chemotherapy. So far chemotherapy-induced intestinal mucositis remains poorly treatable resulting in significant morbidity and reduced quality of life in cancer patients. We investigate how gut microbiota and innate immunity influence toxic side effects of chemotherapy regimens and modulate anti-cancer treatment responses.

Besides ex-vivo 3D-organoids, we use murine in-vivo models of acute intestinal injuries, chronic spontaneous colitis and tumorigenesis in combination with genetic and pharmacologic manipulations to test hypotheses about mucosal homeostasis, cell functions, disease progression and systemic consequences.

Förderung durch: Crohn's and Colitis Foundation of America (CCFA) und Deutsche Forschungsgemeinschaft (DFG)


Wissenschaftliche Mitarbeiter/innen

AG Cario

Dr. rer. nat. Annette Eyking-Singer

Diplom Biologin, Postdoktorandin, AG Cario

AG Cario

Stefanie F. Köhler

M.Sc. Molecular Science, AG Cario

AG Cario

Mareike Rohrbach

M.Sc. Biomedical Engineering, AG Cario


Ehemalige wissenschaftliche Mitarbeiter:

Dr. rer. nat. Eva Maria Hennenberg (2013-2017) Dissertation
Dr. rer. nat. Magdalena Frank (2011-2016) Dissertation
Dr. rer. nat. Frederike Bartsch (2010-2014) Dissertation
Dr. rer. nat. Birgit Ey (2008-2015) Dissertation

 

 


Beispielhafte Projekte der Arbeitsgruppe

Hennenberg EM, Eyking A, Reis H, and Cario E.
PLoS One. 2017 Jul 7;12(7):e0180834. doi: 10.1371/journal.pone.0180834.

Eyking A, Reis H, Frank M, Gerken G, Schmid KW, and Cario E.
PLoS ONE 2016 Jun 6; 11(6): e0156871. doi:10.1371/journal.pone.0156871

Frank M, Hennenberg EM, Eyking A, Rünzi M, Gerken G, Scott P, Parkhill J, Walker AW, Cario E.
J Immunol. 2015 Feb 15;194(4):1983-95. doi: 10.4049/jimmunol.1402481

Ey B, Eyking A, Klepak M, Salzman NH, Göthert JR, Rünzi M, Schmid KW, Gerken G, Podolsky DK, and Cario E.
J Immunol. 2013 Jun 1;190(11):5676-88. doi: 10.4049/jimmunol.1201592

(pdf)

Eyking A, Ey B, Rünzi M, Roig AI, Reis H, Schmid KW, Gerken G, Podolsky DK, and Cario E.
Gastroenterology. 2011 Dec;141(6):2154-65. doi: 10.1053/j.gastro.2011.08.043

(pdf)

Podolsky DK, Gerken G, Eyking A, and Cario E.
Gastroenterology. 2009 Jul;137(1):209-20. doi: 10.1053/j.gastro.2009.03.007

(pdf)

Cario E, Gerken G, Podolsky DK.
Gastroenterology. 2007 Apr;132(4):1359-74. doi: 10.1053/j.gastro.2007.02.056

(pdf)

Cario E, Gerken G, Podolsky DK.
Gastroenterology. 2004 Jul;127(1):224-38. doi: 10.1053/j.gastro.2004.04.015

(pdf)

Prof. Dr. med. Elke Cario
AG Leiterin

Prof. Dr. med. Elke Cario

Leitung AG Experimentelle Gastroenterologie, IG1

+49 201 723 4527 +49 201 723 6858 E-Mail schreiben Zum Steckbrief